Boston Scientific (BSX) Q4 2025 Earnings
How Did BSX Stock React to Q4 2025 Earnings?
S&P 500 over the same 30 days: −1.15%.
Did BSX Beat Earnings? Q4 2025 Results
Yes. Boston Scientific reported Q4 2025 earnings of $0.80 a share on Feb 4, 2026, beating the $0.78 consensus estimate by 2.6%. Revenue was $5.3B against a $5.3B estimate.
Boston Scientific closed out 2025 on a strong note, posting Q4 adjusted EPS of $0.80 against a consensus estimate of $0.78, a 2.56% beat, while revenue of $5.29 billion edged past the $5.28 billion estimate and grew 15.9% year over year. The standout driver was the Cardiovascular segment, which expanded 18.2% on a reported basis to $3.48 billion, powered by continued momentum in cardiac ablation and structural heart therapies; the company is also running a clinical trial combining its FARAPULSE and WATCHMAN devices for atrial fibrillation patients, a move that could further entrench its position in cardiac care. Organic growth of 12.7% for the quarter cleared the company's own 11-to-13 percent guidance range, underscoring the breadth of demand across its portfolio. For full year 2025, net sales reached $20.07 billion with adjusted EPS of $3.06. Looking ahead, management guided 2026 reported revenue growth of 10.5 to 11.5 percent and adjusted EPS of $3.43 to $3.49, signaling continued confidence in its diversified medtech platform.
- Cardiovascular segment grew 18.2% reported and 16.1% organic, driving overall growth
- U.S. region grew 17.0% to $3.385 billion, the strongest regional performer
- Organic growth of 12.7% exceeded the upper end of company guidance of 11-13%
- Adjusted EPS of $0.80 exceeded guidance range of $0.77 to $0.79
“2025 was another exceptional year for Boston Scientific, with our global teams delivering differentiated innovation and high performance that enabled us to exceed our goals. As a direct result of the dedication, consistency and winning spirit of our team, we have impacted millions of patient lives and are well-positioned to continue on our strong growth trajectory well into the future.”
Boston Scientific CEO, on the earnings call
What Was Boston Scientific's Outlook in Q4 2025?
For full year 2026, Boston Scientific estimates net sales growth of approximately 10.5 to 11.5 percent on a reported basis and 10.0 to 11.0 percent on an organic basis versus 2025. Full year 2026 adjusted EPS is expected to be $3.43 to $3.49. For Q1 2026, the company estimates net sales growth of approximately 10.5 to 12.0 percent on a reported basis and 8.5 to 10.0 percent on an organic basis, with adjusted EPS of $0.78 to $0.80.
BSX YoY Financials
| Metric | Q4 2025 | Q4 2024 | Year over year |
|---|---|---|---|
| Revenue | $5.3B | $4.6B | +15.9% |
| Gross Profit | $3.7B | $2.7B | +37.7% |
| Operating Income | $825.0M | $589.0M | +40.1% |
| Net Income | $670.0M | $566.0M | +18.4% |
BSX Revenue by Segment
BSX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.